Bayer Bullish On Consumer Health’s Prospects Despite ‘Challenging’ 2018
Notwithstanding a particularly difficult 2018, Bayer Consumer Health still has "one of the best brand portfolios," and can continue to compete with the market leaders, says CEO Werner Baumann. Consumer Health struggled particularly in the US and Europe in the 12 months, with the majority of its leading brands recording poor performances.
You may also be interested in...
A new dedicated R&D facility for Bayer Consumer Health in China will enable the firm to “quickly take the pulse of the market” and transform demand into innovative products.
Bayer Consumer Health's sales declined at a single-digit rate in the first quarter of 2019, as the business continued to battle challenges in Europe and the US. Undeterred by this slow start to the year, the German firm says Consumer Health's performance will begin to turnaround in the coming months.
Bayer Consumer Health will supply 11 markets across the Americas after investing over $40m to upgrade its manufacturing site in Guatemala, while GSK has announced plans to shut its factory in Nigeria and rely on third-party providers.